The hypoglycemic agents give a critical example: according to INTERCheck, no DDIs are expected between Danazol and these drugs; MEDSCAPE reports that Danazol may increase the effect of Metformin, dipeptidyl peptidase IV inhibitors, or glinides, whereas for UpToDate, Danazol is a hyperglycemia-associated agent who could diminish the therapeutic effects of antidiabetic agents, glifozins included. The gene discussed is DPP4; the disease is Hyperglycemia.